Condition: Cancer · Pancreatic Cancer · Sponsor: British Columbia Cancer Agency
Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients in the future. Changes (mutations) in genes have been shown to be an important characteristic in cancers. Looking at differences in genes in patients with advanced pancreatic ductal adenocarcinomas and comparing this information with response to their initial chemotherapy treatment may help to learn which treatments may be better for certain patients after initial treatment.
This description comes directly from the study's public registry record.
Daniel J Renouf, MD · 800-663-3333 · drenouf@bccancer.bc.ca
Always discuss trial participation with your own doctor first.
| Tom Baker Cancer Centre | Calgary, Alberta, Canada | Recruiting |
| Cross Cancer Institute | Edmonton, Alberta, Canada | Withdrawn |
| BC Cancer - Vancouver | Vancouver, British Columbia, Canada | Recruiting |
| The Ottawa Hospital | Ottawa, Ontario, Canada | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02869802